NCT03411031 2023-03-29Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated18 enrolled 11 charts
NCT03104270 2022-03-31Combination Study for High Risk Multiple Myeloma PatientsOncotherapeuticsPhase 2 Terminated13 enrolled